Seel, your thoughts on the following : how signifi
Post# of 72447
Posted On: 01/08/2014 8:03:18 PM
Seel, your thoughts on the following : how significant or insignificant is this :
Looks like we have a confirmation that Amgen is well aware of Kevetrin, and it's potential as an HDAC inhibitor. Interesting, most interesting. (Even though its obvious to assume that they know quite well of K)
But much more interestingly, why would Kevetrin be mentioned in a patent for AMG-900, a small molecule pan-aurora kinase inhibitor currently in clinical trials for leukemia and solid tumors?
patentimages.storage.googleapis.com/pdfs/US20130323198.pdf
Section 0032 at the end.
I am having trouble posting the excerpt mentioning Kevetrin, but clearly if you go to that page and read that section, it is noteworthy that Amgen would specifically briefly call out Kevetrin as a potential HDAC inhibiting agent that could work effectively with AMG-900.
Of course, AMG-900 itself is in early stage trials, but what's GREAT to me is that Amgen Is calling out Kevetrin in one of their own oncology drug patents. They know what K is and its potential. Of course, I am quite the optimist, so perhaps this is no big deal to most. But it's a damn noteworthy and interesting find to me, at the very least.
So what happens when Amgen hears some potentially riveting data on K from the phase 1 Dana Farber trial?
Pfizer and Celgene, are you going to let Amgen out maneuver you to get Kevetrin?
Exciting times ahead as the K clinical trial advances to cohort 7 safely.
The plot thickens. Thoughts?
Noteworthy? No big deal? Big deal?
Looks like we have a confirmation that Amgen is well aware of Kevetrin, and it's potential as an HDAC inhibitor. Interesting, most interesting. (Even though its obvious to assume that they know quite well of K)
But much more interestingly, why would Kevetrin be mentioned in a patent for AMG-900, a small molecule pan-aurora kinase inhibitor currently in clinical trials for leukemia and solid tumors?
patentimages.storage.googleapis.com/pdfs/US20130323198.pdf
Section 0032 at the end.
I am having trouble posting the excerpt mentioning Kevetrin, but clearly if you go to that page and read that section, it is noteworthy that Amgen would specifically briefly call out Kevetrin as a potential HDAC inhibiting agent that could work effectively with AMG-900.
Of course, AMG-900 itself is in early stage trials, but what's GREAT to me is that Amgen Is calling out Kevetrin in one of their own oncology drug patents. They know what K is and its potential. Of course, I am quite the optimist, so perhaps this is no big deal to most. But it's a damn noteworthy and interesting find to me, at the very least.
So what happens when Amgen hears some potentially riveting data on K from the phase 1 Dana Farber trial?
Pfizer and Celgene, are you going to let Amgen out maneuver you to get Kevetrin?
Exciting times ahead as the K clinical trial advances to cohort 7 safely.
The plot thickens. Thoughts?
Noteworthy? No big deal? Big deal?
(0)
(0)